GO:0050771 negative regulation of axonogenesis: Neuronal Development Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050771 (negative regulation of axonogenesis) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of axonogenesis, the formation and growth of axons.
• Key molecular players include Rho GTPases such as Cdc42 and RAC3, which can either promote or inhibit axon outgrowth depending on context and signaling partners.
• Negative regulation of axonogenesis is critical for proper neural circuit formation, and its dysregulation is linked to neurodevelopmental disorders and cancer.
• Signaling through the p75 neurotrophin receptor can inhibit axonogenesis and promote apoptosis in certain contexts, such as triple-negative breast cancer xenografts.
• Experimental approaches to study this process include genetic knockout, point mutations, knock-in reporters, and overexpression models in primary neurons and animal models.
• Understanding negative regulation of axonogenesis provides insights into neural repair, degeneration, and tumor innervation, with potential therapeutic implications.
Description
Axonogenesis is the developmental process by which neurons extend axons to form functional connections. This process is tightly regulated by both positive and negative signals to ensure proper wiring of the nervous system. GO:0050771, negative regulation of axonogenesis, encompasses all mechanisms that inhibit or reduce axon formation and outgrowth. Researchers study this term to understand how neurons control their morphology, how guidance cues are integrated, and how disruptions contribute to disease. For example, Cdc42 promotes axonogenesis in hippocampal neurons by inhibiting GSK-3β, revealing a negative regulatory node. Similarly, gain-of-function variants in RAC3 disrupt neuronal differentiation and axonogenesis, leading to neurodevelopmental disorders. These findings highlight the importance of negative regulation in both normal development and pathology.
negative regulation of axonogenesis At A Glance
| GO ID | GO:0050771 |
|---|---|
| GO term | negative regulation of axonogenesis |
| Ontology | biological_process |
| Synonym | down regulation of axonogenesis, down-regulation of axonogenesis, downregulation of axonogenesis, inhibition of axonogenesis |
| Major function | Inhibits or reduces the frequency, rate, or extent of axon formation and outgrowth |
| Related processes | Axon guidance, neuron projection development, cytoskeletal organization |
| Key regulators | Rho GTPases (Cdc42, RAC3), GSK-3β, p75 neurotrophin receptor |
| Disease relevance | Neurodevelopmental disorders, cancer, neurodegenerative conditions |
What Is GO:0050771?
According to the Gene Ontology, negative regulation of axonogenesis (GO:0050771) is any process that stops, prevents, or reduces the frequency, rate, or extent of axonogenesis. This includes signaling events, molecular interactions, and cellular changes that inhibit the initiation, growth, or extension of axons. It is a biological process that ensures proper neural circuit formation by balancing growth-promoting and growth-inhibiting cues.
Why Is negative regulation of axonogenesis Important in Cell Biology?
Negative regulation of axonogenesis is essential for proper nervous system development and function. It prevents excessive or aberrant axon growth, ensures correct target innervation, and contributes to synaptic plasticity. Dysregulation of this process is implicated in neurodevelopmental disorders such as those caused by RAC3 mutations, and in cancer progression where nerve outgrowth can influence tumor microenvironment. Understanding the molecular mechanisms of negative regulation provides opportunities for therapeutic intervention in neural injury, degeneration, and cancer.
• Ensures precise wiring of neural circuits by balancing growth-promoting and growth-inhibiting signals.
• Mutations in genes involved in negative regulation, such as RAC3, cause neurodevelopmental disorders.
• Modulates axon regeneration after injury; inhibiting negative regulators may promote repair.
• Influences tumor innervation and cancer progression, as shown in triple-negative breast cancer models.
• Plays a role in neurodegenerative diseases where axonopathy is a feature.
• Provides targets for therapeutic modulation in spinal cord injury and other neural damage.
• Involved in activity-dependent refinement of neural connections during development.
• Cross-talks with apoptosis pathways, as p75 neurotrophin receptor can both inhibit axonogenesis and promote cell death.
• Regulated by extracellular matrix components and growth factors such as GDNF.
• Studied using genome-wide association and pathway analyses to link to Parkinson's disease.
What Happens During negative regulation of axonogenesis?
Initiation of inhibitory signaling
In simple terms: A neuron receives a signal that tells it to stop growing its axon.
Negative regulation of axonogenesis begins when extracellular cues, such as repulsive guidance molecules or neurotrophins like p75 receptor ligands, bind to receptors on the growth cone. This activates intracellular signaling cascades that oppose axon outgrowth. For instance, activation of p75 neurotrophin receptor can inhibit axonogenesis and induce apoptosis in certain contexts. Additionally, intracellular proteins such as Cdc42 can modulate GSK-3β activity to influence axon growth, with Cdc42 promoting axonogenesis by inhibiting GSK-3β, thereby relieving negative regulation.
Cytoskeletal reorganization
In simple terms: The internal skeleton of the neuron is rearranged to stop the axon from extending.
Inhibitory signals lead to changes in actin and microtubule dynamics within the growth cone. Rho GTPases, including RAC3, play critical roles in cytoskeletal reorganization. Gain-of-function mutations in RAC3 disrupt neuronal differentiation and migration, and impair axonogenesis, indicating that proper regulation of Rac3 activity is essential for normal axon outgrowth. Downstream effectors such as WIP and YAP/TAZ connect actin dynamics to transcriptional programs that orchestrate central nervous system development.
Transcriptional and translational control
In simple terms: The cell changes which genes are turned on or off to sustain the stop signal.
Long-term inhibition of axonogenesis involves changes in gene expression. For example, the transcription factor RORA directly regulates multiple genes associated with autism spectrum disorder, some of which are involved in axon guidance and negative regulation of axonogenesis. Pathway analysis of Parkinson's disease genome-wide association studies has highlighted axonogenesis-related pathways, suggesting transcriptional dysregulation contributes to disease.
Integration with apoptosis and survival
In simple terms: Sometimes the stop signal also tells the cell to die.
Negative regulation of axonogenesis can be coupled to apoptotic pathways. In triple-negative breast cancer xenografts, electroacupuncture activates p75 neurotrophin receptor, leading to both inhibition of axonogenesis and increased apoptosis. This dual role underscores the context-dependent outcomes of inhibitory signaling.
Extracellular matrix and glial interactions
In simple terms: The environment around the neuron can send stop signals.
The extracellular matrix (ECM) and glial cells provide inhibitory cues that restrict axon growth. Decellularized ECM enriched with GDNF enhances neurogenesis and remyelination after spinal cord injury, indicating that modifying the ECM can overcome inhibitory signals and promote repair. Thus, negative regulation of axonogenesis is influenced by the cellular microenvironment.
Key Genes Involved in GO:0050771 negative regulation of axonogenesis
The following genes and proteins are key players in negative regulation of axonogenesis, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Cdc42 | Promotes axonogenesis by inhibiting GSK-3β; can also mediate inhibitory signaling depending on context | Studied in primary hippocampal neurons to dissect Rho GTPase signaling in axon growth |
| RAC3 | Gain-of-function mutations disrupt neuronal differentiation, migration, and axonogenesis | Linked to neurodevelopmental disorders; used to model cortical development defects |
| p75NTR | Neurotrophin receptor that can inhibit axonogenesis and promote apoptosis | Targeted in cancer and neural injury models to modulate axon growth |
| GSK-3β | Kinase inhibited by Cdc42; its activity opposes axonogenesis | Investigated as a therapeutic target for promoting axon regeneration |
| RORA | Transcription factor regulating genes associated with autism and axon guidance | Studied for transcriptional control of negative regulation of axonogenesis |
| WIP | Actin-binding protein connecting cytoskeleton to signaling | Implicated in CNS development and transformation |
| YAP/TAZ | Transcriptional co-activators responding to actin dynamics | Regulate gene programs in neural development |
| GDNF | Glial cell line-derived neurotrophic factor; promotes neurogenesis and remyelination | Used in ECM scaffolds for spinal cord injury repair |
| RAGE | Receptor for advanced glycation end-products; may influence axonogenesis in cancer | Reviewed in endometrial cancer context |
| LRP1 | Potential receptor in Parkinson's disease pathways | Identified in pathway analysis of GWAS data |
| DOCK1 | Guanine nucleotide exchange factor for Rac | May modulate Rac3-related signaling |
| PAK1 | Downstream effector of Rac/Cdc42 | Involved in cytoskeletal dynamics during axonogenesis |
| LIMK1 | Regulates actin depolymerization | Potential mediator of inhibitory signaling |
| Cofilin | Actin-severing protein | Regulated by LIMK1 in growth cone collapse |
| ROCK | Rho-associated kinase | Mediates inhibitory signaling from RhoA |
| PTEN | Phosphatase that antagonizes PI3K signaling | Can inhibit axon growth; studied in regeneration |
| SOCS3 | Suppressor of cytokine signaling | Inhibits axon regeneration after injury |
| KLF4 | Transcription factor that can repress axon growth | Investigated in CNS regeneration |
How Is negative regulation of axonogenesis Regulated?
Negative regulation of axonogenesis is controlled by a complex network of signaling pathways. Key regulators include Rho GTPases (Cdc42, Rac3, RhoA), which cycle between active and inactive states to modulate actin dynamics. GSK-3β activity is inhibited by Cdc42 to promote axonogenesis, so factors that activate GSK-3β can enhance negative regulation. The p75 neurotrophin receptor, when activated by ligands such as proNGF, can initiate inhibitory signaling and apoptosis. Transcription factors like RORA regulate gene expression programs that include axon guidance molecules. Extracellular matrix components and glial-derived inhibitors also play major roles, as demonstrated by ECM-based interventions that promote neurogenesis after spinal cord injury. Additionally, pathway analyses have linked axonogenesis-related genes to Parkinson's disease, suggesting that genetic variants in these pathways contribute to disease risk.
negative regulation of axonogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RAC3 | Neurodevelopmental disorder with cortical malformation | Knock-in mouse expressing p.F28S variant; patient-derived iPSCs |
| p75NTR | Triple-negative breast cancer; neural injury | Xenograft mouse models; p75 knockout mice |
| RORA | Autism spectrum disorder | Rora knockout mice; neuronal cultures |
| LRP1 | Parkinson's disease | Lrp1 conditional knockout mice; dopaminergic neurons |
| GDNF | Spinal cord injury | ECM scaffold implantation in rat spinal cord injury model |
Neurodevelopmental disorders
Mutations in genes that regulate axonogenesis can cause neurodevelopmental disorders. For example, a gain-of-function variant in RAC3 (p.F28S) disrupts neuronal differentiation, migration, and axonogenesis during cortical development, leading to neurodevelopmental disorder. This highlights how improper negative regulation of axonogenesis can result in structural brain abnormalities and cognitive deficits.
Cancer
Negative regulation of axonogenesis is relevant to cancer biology. In triple-negative breast cancer xenografts, activation of p75 neurotrophin receptor by electroacupuncture inhibits axonogenesis and promotes apoptosis, suggesting that modulating this process could affect tumor progression. Additionally, RAGE, a receptor involved in cancer, may influence axonogenesis in the tumor microenvironment, as reviewed in endometrial cancer.
Neurodegenerative diseases
Pathway analysis of genome-wide association studies for Parkinson's disease has identified axonogenesis-related pathways, indicating that dysregulation of axon growth and its negative regulation may contribute to neurodegeneration. Understanding these mechanisms could lead to new therapeutic strategies.
Spinal cord injury
After spinal cord injury, inhibitory signals in the extracellular matrix prevent axon regeneration. Decellularized ECM enriched with GDNF enhances neurogenesis and remyelination, improving motor recovery, by overcoming negative regulation of axonogenesis. This demonstrates the therapeutic potential of targeting inhibitory pathways.
From negative regulation of axonogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Cdc42 affect axonogenesis? | Cdc42 knockout mice or primary hippocampal neurons with Cdc42 knockdown |
| How does RAC3 p.F28S mutation alter neuronal migration? | Knock-in mouse expressing RAC3 p.F28S; in utero electroporation |
| Can p75NTR activation inhibit axonogenesis in cancer? | Triple-negative breast cancer xenografts treated with p75 agonist |
| What is the role of RORA in autism-related axon guidance? | Rora knockout mice; RNA-seq of developing cortex |
| Does GDNF-enriched ECM promote axon regeneration? | Rat spinal cord injury model with decellularized ECM + GDNF |
| How do Parkinson's disease risk genes affect axonogenesis? | Human iPSC-derived dopaminergic neurons with risk variants |
How to Study the negative regulation of axonogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Primary neuron culture and transfection | Axon outgrowth and morphology | Testing gene knockdown/overexpression effects |
| Live-cell imaging | Growth cone dynamics and cytoskeletal changes | Real-time observation of inhibitory signaling |
| RNA-seq | Transcriptional changes | Identifying pathways altered by negative regulators |
| ChIP-seq | Transcription factor binding sites | Mapping RORA targets in autism |
| Phosphoproteomics | Kinase activity and signaling networks | Dissecting GSK-3β and Cdc42 pathways |
| In utero electroporation | Neuronal migration and axonogenesis in vivo | Modeling RAC3 gain-of-function |
| Spinal cord injury model | Axon regeneration and functional recovery | Testing ECM+GDNF therapy |
| Xenograft tumor models | Tumor growth and innervation | Evaluating p75NTR effects in cancer |
Genetic manipulation and imaging
To study negative regulation of axonogenesis, researchers often use genetic knockout or knockdown of candidate genes in primary neurons or animal models, followed by imaging of axon outgrowth. For example, Cdc42 was manipulated in hippocampal neurons to assess its role in axonogenesis. Live-cell imaging of growth cones can reveal cytoskeletal dynamics.
Transcriptomics and pathway analysis
RNA sequencing and pathway analysis help identify genes and networks involved in negative regulation. Genome-wide association studies followed by pathway analysis have linked axonogenesis-related genes to Parkinson's disease. Similarly, ChIP-seq for RORA identified direct targets associated with autism.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein expression and phosphorylation during inhibited axon growth. For instance, GSK-3β phosphorylation status is critical for Cdc42-mediated effects. Phosphoproteomics can uncover signaling nodes.
In vivo models and behavioral assays
Animal models, such as spinal cord injury in rats, allow assessment of functional recovery after modulating negative regulators. Decellularized ECM with GDNF was tested in vivo for neurogenesis and motor recovery. Behavioral tests complement histological analysis.
How CRISPR Can Be Used to Study GO:0050771 negative regulation of axonogenesis
Knockout
CRISPR knockout of genes such as Cdc42 or Rac3 can be used to study loss-of-function effects on axonogenesis. For example, knocking out Cdc42 in hippocampal neurons would test its requirement for axon growth and its role in inhibiting GSK-3β. Knockout models help identify essential genes and pathways.
Point Mutation
Introducing specific point mutations, such as the RAC3 p.F28S variant, via CRISPR base editing or homology-directed repair allows researchers to model human neurodevelopmental disorders. This approach revealed that the gain-of-function mutation disrupts neuronal differentiation and axonogenesis.
Knock-in
Knock-in of reporter genes (e.g., fluorescent tags) or disease-associated variants enables tracking of protein localization and function. For instance, tagging endogenous RAC3 with GFP would allow live imaging of its dynamics during axonogenesis. Knock-in of GDNF into ECM-producing cells could enhance regenerative therapies.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can elevate levels of negative regulators like p75NTR or ROCK to study their inhibitory effects. Overexpression of p75NTR in cancer cells might mimic the effects of electroacupuncture-induced inhibition of axonogenesis.
How EDITGENE Supports negative regulation of axonogenesis Research
Researchers studying negative regulation of axonogenesis-related genes often need to determine whether a candidate gene is causally involved in inhibiting axon growth, and to dissect the underlying molecular mechanisms. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant neuronal or cancer cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of axonogenesis research.
Frequently Asked Questions About negative regulation of axonogenesis
What is negative regulation of axonogenesis?
Negative regulation of axonogenesis (GO:0050771) is any biological process that stops, prevents, or reduces the frequency, rate, or extent of axon formation and outgrowth.
What genes are involved in negative regulation of axonogenesis?
Key genes include Cdc42, RAC3, p75NTR, GSK-3β, RORA, and GDNF, among others.
How does Cdc42 regulate axonogenesis?
Cdc42 promotes axonogenesis by inhibiting GSK-3β; thus, its activity can relieve negative regulation.
What diseases are linked to negative regulation of axonogenesis?
Neurodevelopmental disorders, cancer, Parkinson's disease, and spinal cord injury are associated with dysregulation of this process.
What experimental models are used to study negative regulation of axonogenesis?
Primary neuron cultures, knockout mice, knock-in models, and xenograft tumor models are commonly used.
How can CRISPR be used to study negative regulation of axonogenesis?
CRISPR knockout, point mutation, knock-in, and overexpression can manipulate genes like RAC3 or p75NTR to dissect their roles.
What is the role of p75NTR in axonogenesis?
p75 neurotrophin receptor can inhibit axonogenesis and promote apoptosis when activated, as shown in breast cancer models.
Is negative regulation of axonogenesis important for brain development?
Yes, it ensures proper neural circuit formation by balancing growth-promoting and growth-inhibiting signals.
What methods are used to measure negative regulation of axonogenesis?
Imaging of axon outgrowth, RNA-seq, phosphoproteomics, and in vivo models are typical methods.
Can negative regulation of axonogenesis be targeted for spinal cord injury repair?
Yes, overcoming inhibitory signals with GDNF-enriched ECM enhances neurogenesis and motor recovery in animal models.
Conclusion
Negative regulation of axonogenesis (GO:0050771) is a fundamental biological process that ensures proper neural development and function. Its dysregulation contributes to a range of diseases, from neurodevelopmental disorders to cancer and neurodegeneration. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate the molecular mechanisms and identify therapeutic targets. EDITGENE provides comprehensive services to support these investigations.
References
- 1. Li YT et al.. 2022. Cdc42 Promotes Axonogenesis of Primary Hippocampal Neurons by Inhibiting Glycogen Synthase Kinase-3β.. J Integr Neurosci 21(5):133 PMID: 36137969
- 2. Nishikawa M et al.. 2023. Gain-of-function p.F28S variant in RAC3 disrupts neuronal differentiation, migration and axonogenesis during cortical development, leading to neurodevelopmental disorder.. J Med Genet 60(3):223-232 PMID: 35595279
- 3. Tian Y et al.. 2022. Electroacupuncture promotes apoptosis and inhibits axonogenesis by activating p75 neurotrophin receptor for triple-negative breast xenograft in mice.. J Chem Neuroanat 124:102133 PMID: 35777527
- 4. Zglejc-Waszak K et al.. 2024. Role of Receptor for Advanced Glycation End-Products in Endometrial Cancer: A Review.. Cancers (Basel) 16(18) PMID: 39335163
- 5. Song GG et al.. 2013. Pathway analysis of genome-wide association studies for Parkinson's disease.. Mol Biol Rep 40(3):2599-607 PMID: 23238920
- 6. Antón IM et al.. 2021. WIP, YAP/TAZ and Actin Connections Orchestrate Development and Transformation in the Central Nervous System.. Front Cell Dev Biol 9:673986 PMID: 34195190
- 7. Sarachana T et al.. 2013. Genome-wide identification of transcriptional targets of RORA reveals direct regulation of multiple genes associated with autism spectrum disorder.. Mol Autism 4(1):14 PMID: 23697635
- 8. Liu J et al.. 2024. Decellularized extracellular matrix enriched with GDNF enhances neurogenesis and remyelination for improved motor recovery after spinal cord injury.. Acta Biomater 180:308-322 PMID: 38615813
